Roche-Genentech provided a grant for this study (ML 2985). The authors have maintained complete control of all aspects of this study.
This study was presented in part at the annual meeting of the Macula Society in Berlin, Germany, on June 9, 2022, biennial meeting of Club Jules Gonin in Dubrovnik, Croatia, on September 8, 2022, annual meeting of the American Academy of Ophthalmology in Chicago, IL, on September 30 to October 3, 2022; annual meeting of the Retina Society in Pasadena California on November 4, 2022.
Disclosure: C.K. Chan, Roche-Genentech (F), Amgen (F), NEI (F), Chengdu Kanghong (F), Regenerative Patch Technologies (F), Iveric (F), Ocular Therapeutix (R); W.T. Beaulieu, NIH (F), Regeneron (F), Roche-Genentech (F); B.J. Lujan, Roche-Genentech (F), SCDRC (F), Roche-Genentech (C), Regeneron (C), Novartis (C), NGM (C), RegenxBio (C), Lineage (C), Kodiak (C), Ribomic (C), Lujan Imaging (O); M. Lalezary, None; D. Lent-Schochet, None; T. Lo, None; G. Yiu, Clearside Biomedical (F), Genentech (F), Gyroscope Therapeutics (F), Roche-Genentech (F), Alimera (C), Allergan (C), Clearside Biomedical (C), Roch-Genentech (C), Gyroscope Therapeutics (C), Intergalactic Therapeutics (C), Iridex (C), NGM Biopharmaceutical (C), Regeneron (C), Thea (C), Topcon (C), Zeiss (C)